Bristol-Myers Squibb Company (BMY)

$46.65 -1.98 (-4.07%)
Market Cap 94.97B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 7.41
Forward PE 7.43
Profit Margin -18.53%
Debt to Equity Ratio 2.63
Volume 19,779,200
Avg Vol 16,408,068
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 28%
Beta 0.33
Analysts Sell
Price Target $52.61

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
MoneyGroupLLC
MoneyGroupLLC Nov. 16 at 3:30 PM
Enter: $BMY Calls Strike Price: $47 Expiry Date: DEC 05 2025 Buy in Price: $1.70 - $1.78 Sell Price: $2.75 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Nov. 16 at 12:14 PM
$IOVA $5 before end of the year ….. then BO in 2026 …deal with it shorts the pipeline tells all you want to live you will go to Iovance … look who $MRK co hurting with in trials … a combo with Keytruda is game changing …. Others will want is as well $BMY it could be life changing money. It’s rare to mark it bullish but went through the pipeline with my sibling and she is a BP clinical trial manager.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 8:51 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMY Contracts: $BMY December 18, 2026 $47 Calls Scale in: $5.57- $6.81 Scale out: $21.66-$37.12 Profit Potential : 163% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 11:06 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMY $46.50 Put · NOV 21, 2025 Exp Entry Price: $0.80 - $0.96 Exit Price Target: $1.46 Profit Margin: +82% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
scotttrader213
scotttrader213 Nov. 15 at 6:29 PM
$BMY needs a homerun badly. Do what $PFE does! Buy promising companies and pray for a winner!
0 · Reply
framus_morrigan
framus_morrigan Nov. 15 at 12:21 PM
$BMY Shooting star candle at channel resistance & SMA50. Weekly chart.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 15 at 11:19 AM
Enter: $BMY Calls Strike Price: $47 Expiry Date: DEC 05 2025 Buy in Price: $1.70 - $1.78 Sell Price: $2.75 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Theflash88
Theflash88 Nov. 14 at 9:49 PM
$BMY Ok Now buy $VKTX or $ALT or $GPCR or $VTYX Plenty of great companies out there to buy.. MRK just spent $9BILLION on a phase 2 flu vaccine company!
0 · Reply
swingingtech
swingingtech Nov. 14 at 9:35 PM
$DJIA $GLD $BMY $AMAT $XLF Today's market overview is out! https://www.pivotandflowdaily.com/p/november-14th-market-overview
0 · Reply
nlrmandate
nlrmandate Nov. 14 at 7:29 PM
$VKTX Monday would be a GREAT day for $BMY to announce a deal with Viking....After -4% today, their SP needs the boost.....LG Viking!!!
1 · Reply
Latest News on BMY
S&P 500 Gains and Losses Today: DoorDash Drives Higher on a New Partnership; Bristol-Myers Squibb Stock Falls

Nov 14, 2025, 5:30 PM EST - 1 day ago

S&P 500 Gains and Losses Today: DoorDash Drives Higher on a New Partnership; Bristol-Myers Squibb Stock Falls

DASH

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

Nov 14, 2025, 11:17 AM EST - 2 days ago

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 2 days ago

Bristol Myers, J&J halt heart drug trial after interim review

JNJ

Update on Phase 3 Librexia ACS Trial

Nov 14, 2025, 6:59 AM EST - 2 days ago

Update on Phase 3 Librexia ACS Trial

Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research

Nov 12, 2025, 9:00 AM EST - 4 days ago

Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research

Final Trade: UNH, OIH, AMD, BMY

Nov 11, 2025, 6:28 PM EST - 4 days ago

Final Trade: UNH, OIH, AMD, BMY

AMD OIH UNH

Jim Cramer Is Backing Off Bristol-Myers, But These 2 Chinese Stocks Are Good

Nov 11, 2025, 8:08 AM EST - 5 days ago

Jim Cramer Is Backing Off Bristol-Myers, But These 2 Chinese Stocks Are Good

BABA BIDU FXI JD KWEB MCHI PDD

Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

Nov 5, 2025, 2:47 PM EST - 10 days ago

Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

Bristol Myers reaches $239 million settlement over psoriasis, MS drugs

Nov 5, 2025, 11:36 AM EST - 11 days ago

Bristol Myers reaches $239 million settlement over psoriasis, MS drugs

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

Nov 4, 2025, 9:00 AM EST - 12 days ago

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

Bristol-Myers Squibb: Way Too Cheap At 7x P/E

Nov 4, 2025, 8:00 AM EST - 12 days ago

Bristol-Myers Squibb: Way Too Cheap At 7x P/E

Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth

Nov 3, 2025, 6:06 PM EST - 12 days ago

Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 13 days ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BNTX

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 13 days ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN LLY MBX MDGL MEDI

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025

Nov 3, 2025, 6:59 AM EST - 13 days ago

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

Nov 3, 2025, 4:55 AM EST - 13 days ago

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

Final Trades: Rocket Companies, Meta, Cleveland-Cliffs, Bristol Myers

Oct 31, 2025, 1:33 PM EDT - 16 days ago

Final Trades: Rocket Companies, Meta, Cleveland-Cliffs, Bristol Myers

CLF META RKT

Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 4:06 PM EDT - 16 days ago

Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript

Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook

Oct 30, 2025, 2:55 PM EDT - 16 days ago

Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook

Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead

Oct 30, 2025, 1:22 PM EDT - 17 days ago

Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead

10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)

Oct 30, 2025, 11:51 AM EDT - 17 days ago

10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)

BBVA CMCSA EOG EPD ET HMC ITUB

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.

Oct 30, 2025, 7:32 AM EDT - 17 days ago

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.

Bristol Myers Squibb Profit Soars, Raises Revenue Guidance

Oct 30, 2025, 7:11 AM EDT - 17 days ago

Bristol Myers Squibb Profit Soars, Raises Revenue Guidance

Bristol Myers beats quarterly revenue estimates on strong Opdivo sales

Oct 30, 2025, 7:03 AM EDT - 17 days ago

Bristol Myers beats quarterly revenue estimates on strong Opdivo sales

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

Oct 30, 2025, 6:59 AM EDT - 17 days ago

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

3 Investable Laggards In An Overbought Market

Oct 28, 2025, 5:13 PM EDT - 18 days ago

3 Investable Laggards In An Overbought Market

AVDL ETNB MRUS MTSR NVS PAGP RNA

Bristol-Myers Squibb: Earnings Champion Valued Like A Loser

Oct 27, 2025, 9:13 AM EDT - 20 days ago

Bristol-Myers Squibb: Earnings Champion Valued Like A Loser

Is It Time To Buy BMY Stock?

Oct 27, 2025, 8:00 AM EDT - 20 days ago

Is It Time To Buy BMY Stock?

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Oct 27, 2025, 6:59 AM EDT - 20 days ago

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Oct 27, 2025, 2:50 AM EDT - 20 days ago

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

EVO

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

Oct 25, 2025, 11:00 AM EDT - 22 days ago

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs

Oct 24, 2025, 7:54 AM EDT - 23 days ago

Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs

BBB CAG EQR KEY KIM LYB MO

Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare

Oct 23, 2025, 5:20 PM EDT - 23 days ago

Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare

These low-risk stocks could be a profitable answer to this volatile earnings season

Oct 23, 2025, 10:52 AM EDT - 24 days ago

These low-risk stocks could be a profitable answer to this volatile earnings season

AMGN CVS GD GIS HQY HRL JNJ

The Play On Bristol-Myers Squibb

Oct 21, 2025, 11:27 AM EDT - 26 days ago

The Play On Bristol-Myers Squibb

My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 27 days ago

My Top 3 Pharma Stocks

AKRO ETNB LLY MRK NVO PFE SPY

October's 5 Dividend Growth Stocks With Yields Up To 8.33%

Oct 20, 2025, 11:34 AM EDT - 27 days ago

October's 5 Dividend Growth Stocks With Yields Up To 8.33%

IYR MO RLJ UPS VICI XLV

Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More

Oct 17, 2025, 10:17 AM EDT - 4 weeks ago

Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More

NNE ZETA CSWC ENVX ET HTGC JPM

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

Oct 17, 2025, 10:00 AM EDT - 4 weeks ago

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields

Oct 15, 2025, 7:15 AM EDT - 4 weeks ago

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields

PFE PRGO

Final Trade: WMT, AMZN, F, BMY

Oct 14, 2025, 6:20 PM EDT - 4 weeks ago

Final Trade: WMT, AMZN, F, BMY

AMZN WMT F

Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics

Oct 13, 2025, 7:30 AM EDT - 4 weeks ago

Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

Oct 13, 2025, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

Oct 13, 2025, 5:00 AM EDT - 4 weeks ago

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Oct 12, 2025, 10:11 AM EDT - 5 weeks ago

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

AES AMCR ARE CAG CPB DOC DOW

Bristol Myers Squibb: Value Emerges From Distress

Oct 11, 2025, 9:52 AM EDT - 5 weeks ago

Bristol Myers Squibb: Value Emerges From Distress

Bristol Myers buys Orbital Therapeutics for $1.5 billion

Oct 10, 2025, 7:05 AM EDT - 5 weeks ago

Bristol Myers buys Orbital Therapeutics for $1.5 billion

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

Oct 10, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

Oct 10, 2025, 6:45 AM EDT - 5 weeks ago

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield

Oct 9, 2025, 12:00 PM EDT - 5 weeks ago

Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield

MoneyGroupLLC
MoneyGroupLLC Nov. 16 at 3:30 PM
Enter: $BMY Calls Strike Price: $47 Expiry Date: DEC 05 2025 Buy in Price: $1.70 - $1.78 Sell Price: $2.75 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Nov. 16 at 12:14 PM
$IOVA $5 before end of the year ….. then BO in 2026 …deal with it shorts the pipeline tells all you want to live you will go to Iovance … look who $MRK co hurting with in trials … a combo with Keytruda is game changing …. Others will want is as well $BMY it could be life changing money. It’s rare to mark it bullish but went through the pipeline with my sibling and she is a BP clinical trial manager.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 8:51 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMY Contracts: $BMY December 18, 2026 $47 Calls Scale in: $5.57- $6.81 Scale out: $21.66-$37.12 Profit Potential : 163% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 11:06 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMY $46.50 Put · NOV 21, 2025 Exp Entry Price: $0.80 - $0.96 Exit Price Target: $1.46 Profit Margin: +82% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
scotttrader213
scotttrader213 Nov. 15 at 6:29 PM
$BMY needs a homerun badly. Do what $PFE does! Buy promising companies and pray for a winner!
0 · Reply
framus_morrigan
framus_morrigan Nov. 15 at 12:21 PM
$BMY Shooting star candle at channel resistance & SMA50. Weekly chart.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 15 at 11:19 AM
Enter: $BMY Calls Strike Price: $47 Expiry Date: DEC 05 2025 Buy in Price: $1.70 - $1.78 Sell Price: $2.75 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Theflash88
Theflash88 Nov. 14 at 9:49 PM
$BMY Ok Now buy $VKTX or $ALT or $GPCR or $VTYX Plenty of great companies out there to buy.. MRK just spent $9BILLION on a phase 2 flu vaccine company!
0 · Reply
swingingtech
swingingtech Nov. 14 at 9:35 PM
$DJIA $GLD $BMY $AMAT $XLF Today's market overview is out! https://www.pivotandflowdaily.com/p/november-14th-market-overview
0 · Reply
nlrmandate
nlrmandate Nov. 14 at 7:29 PM
$VKTX Monday would be a GREAT day for $BMY to announce a deal with Viking....After -4% today, their SP needs the boost.....LG Viking!!!
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:49 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMY $46.50 Put · NOV 21, 2025 Exp Entry Price: $0.84 - $0.87 Exit Price Target: $1.70 Profit Margin: +102% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Cashflow62
Cashflow62 Nov. 14 at 5:55 PM
$BMY Apparently Doesn't seem to matter much they had a "failure." Stock is only down 2.8%. Hardly warrants the latest news release hype of, "yet another failure....."
0 · Reply
TradingLive
TradingLive Nov. 14 at 5:09 PM
$BMY Will it ever have any sustainable and positive news? Guess not..!
0 · Reply
sluggowski
sluggowski Nov. 14 at 4:18 PM
$BMY Wierd, its still green for the week but down -3.68% today. 5% dividend and a Buy Rating on SA. I'm in for a reload. I got an itch for for the dividends....
0 · Reply
sluggowski
sluggowski Nov. 14 at 4:12 PM
$BMY what the **** is going on with BMY?
0 · Reply
hadababymama
hadababymama Nov. 14 at 3:26 PM
$BMY retest, before run to $52.50
1 · Reply
QuantitativeTrading_
QuantitativeTrading_ Nov. 14 at 2:18 PM
$BMY https://stocktwits.com/news-articles/markets/equity/bmy-stock-slumps-after-it-scraps-heart-drug-study/cLPQOJeRE4Q
0 · Reply
lebranjames
lebranjames Nov. 14 at 2:05 PM
$BMY this should get killed today, the success of milvexian was the answer to Eliquis pending patent loss. Not to mention the billions spent to run 50 K patient international clinical trials. Very disappointing.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 14 at 1:41 PM
$BMY $JNJ
0 · Reply
Lincoln_Osiris
Lincoln_Osiris Nov. 14 at 1:41 PM
$BMY I'm down ~75K the last two weeks. Looking for a "safe buy" today, so buying more BMY. Have to park it somewhere and can't think of a better place.
1 · Reply
OpenOutcrier
OpenOutcrier Nov. 14 at 1:30 PM
$BMY (-5.2% pre) Bristol Myers Squibb discontinues milvexian ACS trial after review https://ooc.bz/l/84551
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 14 at 1:28 PM
BMY Stock Slumps 5% After It Scraps Heart Drug Study $BMY $DUHP $JNJ https://stocktwits.com/news/equity/markets/bmy-stock-slumps-after-it-scraps-heart-drug-study/cLPQOJeRE4Q
0 · Reply